MX2022003346A - Dosage forms and methods for enantiomerically enriched or pure bupropion. - Google Patents
Dosage forms and methods for enantiomerically enriched or pure bupropion.Info
- Publication number
- MX2022003346A MX2022003346A MX2022003346A MX2022003346A MX2022003346A MX 2022003346 A MX2022003346 A MX 2022003346A MX 2022003346 A MX2022003346 A MX 2022003346A MX 2022003346 A MX2022003346 A MX 2022003346A MX 2022003346 A MX2022003346 A MX 2022003346A
- Authority
- MX
- Mexico
- Prior art keywords
- dosage forms
- bupropion
- enantiomerically enriched
- methods
- pure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/052210 WO2020061486A2 (en) | 2018-09-20 | 2019-09-20 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US202062971174P | 2020-02-06 | 2020-02-06 | |
| US202062978626P | 2020-02-19 | 2020-02-19 | |
| US202062992060P | 2020-03-19 | 2020-03-19 | |
| US16/830,637 US20200222339A1 (en) | 2018-09-20 | 2020-03-26 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US16/907,691 US11433035B2 (en) | 2018-09-20 | 2020-06-22 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| PCT/US2020/046755 WO2021055124A1 (en) | 2019-09-20 | 2020-08-18 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022003346A true MX2022003346A (en) | 2022-04-11 |
Family
ID=74884634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003346A MX2022003346A (en) | 2019-09-20 | 2020-08-18 | Dosage forms and methods for enantiomerically enriched or pure bupropion. |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP4031121A4 (en) |
| JP (2) | JP2022549192A (en) |
| KR (1) | KR20220066930A (en) |
| CN (1) | CN114423417A (en) |
| AU (2) | AU2020349419B2 (en) |
| BR (1) | BR112022005045A2 (en) |
| CA (1) | CA3154718A1 (en) |
| CO (1) | CO2022003126A2 (en) |
| CR (1) | CR20220119A (en) |
| EC (1) | ECSP22030119A (en) |
| IL (1) | IL291514A (en) |
| MX (1) | MX2022003346A (en) |
| PE (1) | PE20221314A1 (en) |
| WO (1) | WO2021055124A1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1051166A1 (en) * | 1998-01-29 | 2000-11-15 | Sepracor, Inc. | Pharmaceutical uses of optically pure (+) -bupropion |
| US6150420A (en) * | 1998-06-01 | 2000-11-21 | Theramax, Inc. | Method for enhanced brain delivery of bupropion |
| US20190216800A1 (en) * | 2013-11-05 | 2019-07-18 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| MX2013014166A (en) * | 2013-12-03 | 2015-06-10 | Inst De Investigacion En Quimica Aplic S A De C V | Active enantiomers and the salts thereof for treating obesity. |
| US9732031B2 (en) * | 2013-12-20 | 2017-08-15 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
| MX2020008704A (en) * | 2018-02-23 | 2020-12-07 | Axsome Therapeutics Inc | Dosage forms and methods for enantiomerically enriched or pure bupropion. |
-
2020
- 2020-08-18 MX MX2022003346A patent/MX2022003346A/en unknown
- 2020-08-18 WO PCT/US2020/046755 patent/WO2021055124A1/en unknown
- 2020-08-18 BR BR112022005045A patent/BR112022005045A2/en unknown
- 2020-08-18 AU AU2020349419A patent/AU2020349419B2/en active Active
- 2020-08-18 PE PE2022000441A patent/PE20221314A1/en unknown
- 2020-08-18 KR KR1020227013095A patent/KR20220066930A/en active Search and Examination
- 2020-08-18 JP JP2022517743A patent/JP2022549192A/en active Pending
- 2020-08-18 CN CN202080065520.4A patent/CN114423417A/en active Pending
- 2020-08-18 CR CR20220119A patent/CR20220119A/en unknown
- 2020-08-18 EP EP20866164.5A patent/EP4031121A4/en active Pending
- 2020-08-18 CA CA3154718A patent/CA3154718A1/en active Pending
-
2022
- 2022-03-18 CO CONC2022/0003126A patent/CO2022003126A2/en unknown
- 2022-03-20 IL IL291514A patent/IL291514A/en unknown
- 2022-04-13 EC ECSENADI202230119A patent/ECSP22030119A/en unknown
-
2024
- 2024-01-05 AU AU2024200081A patent/AU2024200081A1/en active Pending
- 2024-02-22 JP JP2024025971A patent/JP2024059812A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024059812A (en) | 2024-05-01 |
| KR20220066930A (en) | 2022-05-24 |
| EP4031121A1 (en) | 2022-07-27 |
| CO2022003126A2 (en) | 2022-04-19 |
| CR20220119A (en) | 2022-06-22 |
| AU2020349419B2 (en) | 2023-11-02 |
| CN114423417A (en) | 2022-04-29 |
| BR112022005045A2 (en) | 2022-07-05 |
| IL291514A (en) | 2022-05-01 |
| ECSP22030119A (en) | 2022-05-31 |
| AU2024200081A1 (en) | 2024-01-25 |
| PE20221314A1 (en) | 2022-09-07 |
| EP4031121A4 (en) | 2022-11-30 |
| CA3154718A1 (en) | 2021-03-25 |
| AU2020349419A1 (en) | 2022-03-24 |
| JP2022549192A (en) | 2022-11-24 |
| WO2021055124A1 (en) | 2021-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020061486A3 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| ZA202110659B (en) | Methods of reducing the risk of cardiovascular events in a subject | |
| PH12020500066A1 (en) | Carboxamides as modulators of sodium channels | |
| SG10201810888XA (en) | Compositions and methods comprising bupropion or related compounds and dextromethorphan | |
| MX2023003778A (en) | Antitumor compound, and preparation method therefor and use thereof. | |
| MX2016010235A (en) | Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor. | |
| EP3755312A4 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| MX2023000187A (en) | Dosing of vibegron for treatment of overactive bladder. | |
| MX2022015629A (en) | Use of vibegron to treat overactive bladder. | |
| GEP20247585B (en) | Furoindazole derivatives | |
| MX2021013354A (en) | Methods of treating and/or preventing actinic keratosis. | |
| WO2018178243A3 (en) | Dihydrotetrabenazine for use in the treatment a movement disorder | |
| MX2021007142A (en) | Organic compounds. | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| MX2022003346A (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion. | |
| EP3818981A4 (en) | Synergic pharmaceutical composition of the active enantiomer (s)-ketorolac and gabapentin for the treatment of neuropathic pain | |
| MX2016014740A (en) | A method for treating movement disorders with befiradol. | |
| MX2018013324A (en) | Methods and compositions for treatment of rett syndrome. | |
| PH12021500016A1 (en) | Methods of reducing the risk of cardiovascular events in a subject | |
| EA202191907A1 (en) | APPLICATION OF VIBEGRON FOR TREATMENT OF HYPERACTIVE BLADDER | |
| AU2017202335A1 (en) | Hangover cure. | |
| MX2023005681A (en) | Pharmaceutical composition for treating acute and chronic pain, containing polmacoxib and tramadol. | |
| UA108990C2 (en) | Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions | |
| UA27828U (en) | Method for treating prosthetic stomatitis against the background metabolic syndrome | |
| UA27830U (en) | Method for treating prosthetic stomatitis against the background of metabolic syndrome |